Marty Makary’s tenure as commissioner of the Food and Drug Administration (FDA) concluded abruptly on Tuesday with his resignation, a…
Read More
Probiotic Yogurt Strain May Boost Immunotherapy Response in Lung Cancer, Small Study Suggests
San Diego, CA — In a development that could herald a novel adjunct to conventional cancer therapies, interim clinical data…
Read More
Novo Nordisk Hands a Parkinson’s Cell Therapy to Cellular Intelligence, a Startup Trying to Design Cell Behavior
In a significant move poised to reshape the landscape of Parkinson’s disease treatment and the broader cell therapy sector, Cellular…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The Unapproved QUAD Cocktail: A Closer Look at its Composition QUAD is a compounded sublingual dose product marketed by MEDVi…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
Covalent drugs, a class of therapeutics that form irreversible or quasi-irreversible bonds with their biological targets, have undergone a remarkable…
Read More
Sai Life Sciences’ Biotech Pitch Day 2026 Unveils Groundbreaking Innovations from Early-Stage Biotechs, Reinforcing Global Drug Discovery Ecosystem
Sai Life Sciences, a leading global contract research, development, and manufacturing organization (CRDMO), recently convened its highly anticipated Biotech Pitch…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The fiscal year 2025 concluded with a dramatic reshuffling at the pinnacle of the pharmaceutical industry’s sales leaderboard, signaling profound…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The dramatic rise of GLP-1 agonists, once hailed as a universal panacea for the global obesity epidemic, is increasingly being…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read MoreYOU MAY HAVE MISSED
